PTPRC and cancer: In patients with cancer, abundant CD45+EPCs are accumulated in the spleen, producing reactive oxygen species (ROS), which inhibits systemic anti-tumor immunity, and CD45+EPCs promote tumor progression through CD8 T-cell immunosuppression [56].